English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe Icahn School of Medicine at Mount Sinai in New York, NY is pleased to announce that CastleVax, Inc. has completed enrollment and a preliminary analysis of a phase 1 trial of its licensed Newcastle disease virus (NDV)-based COVID-19 booster vaccine.
Tag: Florian Krammer
Royalty Pharma Donates $1,000,000 To Support Mount Sinai’s COVID-19 Patient Care and Clinical Research
Royalty Pharma today announced a charitable contribution by Royalty Pharma in the amount of $1,000,000 to Mount Sinai Health System.
Study Finds 1.7 Million New Yorkers Have Been infected with SARS-Cov-2 and Virus was in NYC Earlier than Reported
The virus that causes COVID-19 was present in New York City long before the city’s first case of the disease was confirmed on March 1
Most People Mount a Strong Antibody Response to SARS-CoV-2 That Does Not Decline Rapidly
The vast majority of individuals infected with mild-to-moderate COVID 19 mount a robust antibody response that is relatively stable for at least five months, according to research conducted at the Icahn School of Medicine at Mount Sinai and published October 28, in the journal Science.
New York State Department of Health Grants Emergency Use Authorization to Mount Sinai for Quantitative COVID-19 Antibody Test
The Clinical Laboratories of The Mount Sinai Hospital has received emergency use authorization from the New York State Department of Health (NYSDOH) for quantitative use of Mount Sinai’s COVID-19 antibody test, making Mount Sinai’s lab the first in the country to run an authorized, fully quantitative antibody test that can deliver a precise numeric measurement of the level of antibodies in a patient’s blood
Mount Sinai study finds SARS-CoV-2 induces robust antibody responses stable for at least 3 months
Research from the Mount Sinai Health System, just posted to pre-print server MedRxiv (https://www.medrxiv.org/content/10.1101/2020.07.14.20151126v1), shows that the vast majority (more than 90%) of infected individuals with mild-to-moderate COVID 19 experience robust IgG antibody responses against the viral spike protein. The researchers also show…
High-Accuracy COVID-19 Antibody Testing Begins in Arkansas
The University of Arkansas for Medical Sciences (UAMS) has developed and begun using high-accuracy antibody testing to determine the magnitude of COVID-19 infection in Arkansas and inform the decisions of policymakers.
Mount Sinai seeks EUA from Food and Drug Administration for potential quantitative serologic test for COVID-19
If authorized for quantitative use, the assay could be used to provide a numeric result for the concentration of neutralizing anti-COVID-19 antibodies in plasma.
Mount Sinai Health System and Renalytix Form Joint Venture, Kantaro Biosciences, To Develop and Scale Production of COVID Antibody Test Kits
– Kantaro Biosciences partners with Bio-Techne for manufacturing and global kit distribution
– Scaled kit production to enable clinical laboratories to conduct 10M tests per month is planned to begin in July